. 2017 Dec 1;9:559–565. doi: 10.2147/BCTT.S148080

Table 1.

Overview of the association between statin use and risk of recurrence after multivariate analysis

Study	Type	N	Stage	Statins	Recurrence
Kwan et al¹²	Prospective	1,945	I–IIIA	Lipophilic (97.8%)		RR	95% CI
				Hydrophilic (2.2%)	>100 days	0.67	0.39–1.13
				Hydrophilic (2.2%)	>2 years	0.38	0.12–1.19
Ahern et al¹³	Prospective	18,769	I–III	Lipophilic (77.6%), simvastatin (71.7%)		HR	95% CI
				Hydrophilic (22.3%)	5-Year lipophilic	0.7	0.53–0.92
					5-Year simvastatin	0.62	0.46–0.84
					5-Year hydrophilic	1.1	0.7–1.80
					10-Year lipophilic	0.73	0.6–0.89
					10-Year simvastatin	0.7	0.57–0.86
					10-Year hydrophilic	1.2	0.79–1.7
Chae et al¹⁵	Retrospective	703	II–III	Lipophilic (87.6%), atorvastatin (60.2%)		HR	95% CI
				Hydrophilic (12.4%)	Statins only	0.4	0.24–0.67
				Hydrophilic (12.4%)	Statins + ACEi/ARBs	0.3	0.15–0.61
Boudreau et al¹⁶	Prospective	4,216	I–IIB	Lipophilic, simvastatin (60.39%), fluvastatin (49.34%)		HR	95% CI
				Hydrophilic (3.63)	<1 year	0.94	0.51–1.75
					1–2.9 years	0.66	0.34–1.30
					3+ years	0.77	0.42–1.41
					Trend	0.89	0.74–1.08
Sakellakis et al¹⁷	Retrospective	610	I–III	Lipophilic (64%), atorvastatin (45%)		HR	95% CI
Sakellakis et al¹⁷	Retrospective	610	I–III	Hydrophilic (16%)	All statin users	0.58	0.36–0.94
Brewer et al¹⁸	Retrospective	73	III (IBC)	Lipophilic (39.7%)		HR	95% CI
Brewer et al¹⁸	Retrospective	73	III (IBC)	Hydrophilic (60.3%)	Hydrophilic only	0.49	0.28–0.84
Lacerda et al³⁹	Retrospective	53	III (IBC)			HR	95% CI
Lacerda et al³⁹	Retrospective	53	III (IBC)		All statin users	0.4	0.16–1.00
Manthravadi et al¹⁴	Meta-analysis	75,684; 14 studies	I–IV	All		HR	95% CI
					All statins (10 studies)	0.64	0.53–0.79
					Lipophilic (three studies)	0.72	0.59–0.89
					Hydrophilic (three studies)	0.8	0.44–1.46

Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CI, confidence interval; HR, hazard ratio; IBC, inflammatory breast cancer; N, number; RR, relative risk.